The earnings call reflected a strong financial performance with significant revenue and profit growth, successful FDA approvals, and raised guidance. However, there were challenges including a decline in OUS revenue and anticipated seasonality impacts, alongside addressing competitive noise. Overall, the positive highlights significantly outweighed the lowlights.

Company Guidance

During the TransMedics second quarter 2025 earnings call, the company provided a robust set of financial and operational metrics that underscored their strong performance and future growth strategies. The company reported total revenue of $157.4 million for the quarter, representing approximately 38% growth year-over-year and about 10% sequential growth from the first quarter of 2025. Gross margin remained steady at 61.4%, similar to the previous quarter, while operating profit increased to $36.6 million, up from $27.4 million in the prior quarter. The company also highlighted a significant addition of approximately $90 million to its balance sheet, ending the quarter with over $400 million in cash. TransMedics raised its full-year 2025 revenue guidance to between $585 million and $605 million, reflecting approximately 35% growth over 2024 at the midpoint. The company also discussed its strategic initiatives, including achieving 10,000 U.S. NOP transplants by 2028, exploring international expansion, and advancing clinical programs for its next-gen OCS Heart and Lung platforms. Despite expected minor seasonal fluctuations in the third quarter, TransMedics remains focused on sustaining its upward momentum and expanding its market presence.

Record Revenue Growth

Total revenue for 2Q 2025 was $157.4 million, representing approximately 38% growth year-over-year and approximately 10% sequential growth from 1Q 2025.

Strong Operating Profit and Cash Generation

Operating profit of approximately $36.6 million in 2Q, representing more than 23% of total revenue, and strong cash generation with over $400 million in cash at the end of 2Q.

Growth in Transplant Logistics Revenue

Transplant logistics service revenue for 2Q was $29.8 million, representing 56% year-over-year and 14% sequential growth.

FDA Conditional Approval for OCS Lung IDE

Received FDA conditional approval for the OCS Lung IDE in July, with plans to begin trial initiation activities soon.

Raised Full Year 2025 Revenue Guidance

Raised full year 2025 revenue guidance to between $585 million and $605 million, representing approximately 35% growth over full year 2024.

TransMedics Group (TMDX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TMDX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.36 / -	0.12	―	―	―
Jul 30, 2025	2025 (Q2)	0.45 / 0.92	0.35	162.86% (+0.57)
May 08, 2025	2025 (Q1)	0.26 / 0.70	0.35	100.00% (+0.35)	―
Feb 27, 2025	2024 (Q4)	0.16 / 0.19	0.12	58.33% (+0.07)	―
Oct 28, 2024	2024 (Q3)	0.29 / 0.12	-0.78	115.38% (+0.90)	―
Jul 31, 2024	2024 (Q2)	0.21 / 0.35	-0.03	1266.67% (+0.38)	―
Apr 30, 2024	2024 (Q1)	-0.02 / 0.35	-0.08	537.50% (+0.43)	―
Feb 26, 2024	2023 (Q4)	-0.07 / 0.12	-0.21	157.14% (+0.33)	―
Nov 06, 2023	2023 (Q3)	-0.16 / -0.78	-0.25	-212.00% (-0.53)	―
Aug 03, 2023	2023 (Q2)	-0.13 / -0.03	-0.41	92.68% (+0.38)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TMDX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$107.70	$118.97	+10.46%
May 08, 2025	$93.20	$111.50	+19.64%
Feb 27, 2025	$72.12	$76.32	+5.82%
Oct 28, 2024	$126.24	$88.50	-29.90%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does TransMedics Group Inc (TMDX) report earnings?

TransMedics Group Inc (TMDX) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is TransMedics Group Inc (TMDX) earnings time?

TransMedics Group Inc (TMDX) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TMDX EPS forecast?

TMDX EPS forecast for the fiscal quarter 2025 (Q3) is 0.36.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing